vs
OFG BANCORP（OFG）与VERACYTE, INC.（VCYT）财务数据对比。点击上方公司名可切换其他公司
OFG BANCORP的季度营收约是VERACYTE, INC.的1.3倍（$184.3M vs $140.6M），OFG BANCORP净利率更高（30.3% vs 29.3%，领先1.1%），VERACYTE, INC.同比增速更快（18.5% vs 0.9%），OFG BANCORP自由现金流更多（$199.3M vs $48.8M），过去两年VERACYTE, INC.的营收复合增速更高（20.5% vs 2.8%）
OFG Bancorp成立于1964年，总部位于波多黎各圣胡安，是东方银行的金融控股公司。公司通过东方银行、东方金融服务有限责任公司、东方保险有限责任公司等核心子公司，主要面向波多黎各和美属维尔京群岛市场，提供多元化的零售与商业银行、贷款、财富管理相关产品、服务及技术解决方案。
Veracyte是一家领先的分子诊断企业，专注开发专有的基因组检测方案，可实现癌症及其他复杂疾病的早期精准检测，产品服务于医疗机构以优化临床决策，核心市场位于美国，正稳步拓展全球业务布局。
OFG vs VCYT — 直观对比
营收规模更大
OFG
是对方的1.3倍
$140.6M
营收增速更快
VCYT
高出17.7%
0.9%
净利率更高
OFG
高出1.1%
29.3%
自由现金流更多
OFG
多$150.5M
$48.8M
两年增速更快
VCYT
近两年复合增速
2.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $184.3M | $140.6M |
| 净利润 | $55.9M | $41.1M |
| 毛利率 | — | 72.5% |
| 营业利润率 | 25.7% | 26.4% |
| 净利率 | 30.3% | 29.3% |
| 营收同比 | 0.9% | 18.5% |
| 净利润同比 | 11.0% | 704.8% |
| 每股收益（稀释后） | $1.27 | $0.50 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OFGVCYT
| Q4 25 | $184.3M | $140.6M | ||
| Q3 25 | $186.2M | $131.9M | ||
| Q2 25 | $182.4M | $130.2M | ||
| Q1 25 | $178.6M | $114.5M | ||
| Q4 24 | $182.7M | $118.6M | ||
| Q3 24 | $174.7M | $115.9M | ||
| Q2 24 | $179.8M | $114.4M | ||
| Q1 24 | $174.4M | $96.8M |
净利润OFGVCYT
| Q4 25 | $55.9M | $41.1M | ||
| Q3 25 | $51.8M | $19.1M | ||
| Q2 25 | $51.8M | $-980.0K | ||
| Q1 25 | $45.6M | $7.0M | ||
| Q4 24 | $50.3M | $5.1M | ||
| Q3 24 | $47.0M | $15.2M | ||
| Q2 24 | $51.1M | $5.7M | ||
| Q1 24 | $49.7M | $-1.9M |
毛利率OFGVCYT
| Q4 25 | — | 72.5% | ||
| Q3 25 | — | 69.2% | ||
| Q2 25 | — | 69.0% | ||
| Q1 25 | — | 69.5% | ||
| Q4 24 | — | 66.4% | ||
| Q3 24 | — | 68.2% | ||
| Q2 24 | — | 68.1% | ||
| Q1 24 | — | 64.5% |
营业利润率OFGVCYT
| Q4 25 | 25.7% | 26.4% | ||
| Q3 25 | 33.0% | 17.4% | ||
| Q2 25 | 36.1% | -4.0% | ||
| Q1 25 | 33.3% | 2.5% | ||
| Q4 24 | 28.9% | 3.5% | ||
| Q3 24 | 35.4% | 10.4% | ||
| Q2 24 | 39.6% | 4.0% | ||
| Q1 24 | 38.9% | -4.8% |
净利率OFGVCYT
| Q4 25 | 30.3% | 29.3% | ||
| Q3 25 | 27.8% | 14.5% | ||
| Q2 25 | 28.4% | -0.8% | ||
| Q1 25 | 25.5% | 6.2% | ||
| Q4 24 | 27.6% | 4.3% | ||
| Q3 24 | 26.9% | 13.1% | ||
| Q2 24 | 28.4% | 5.0% | ||
| Q1 24 | 28.5% | -1.9% |
每股收益（稀释后）OFGVCYT
| Q4 25 | $1.27 | $0.50 | ||
| Q3 25 | $1.16 | $0.24 | ||
| Q2 25 | $1.15 | $-0.01 | ||
| Q1 25 | $1.00 | $0.09 | ||
| Q4 24 | $1.10 | $0.07 | ||
| Q3 24 | $1.00 | $0.19 | ||
| Q2 24 | $1.08 | $0.07 | ||
| Q1 24 | $1.05 | $-0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.0B | $362.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.4B | $1.3B |
| 总资产 | $12.5B | $1.4B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资OFGVCYT
| Q4 25 | $1.0B | $362.6M | ||
| Q3 25 | $740.3M | $315.6M | ||
| Q2 25 | $851.8M | $219.5M | ||
| Q1 25 | $710.6M | $186.1M | ||
| Q4 24 | $591.1M | $239.1M | ||
| Q3 24 | $680.6M | $274.1M | ||
| Q2 24 | $740.4M | $235.9M | ||
| Q1 24 | $754.4M | $209.2M |
股东权益OFGVCYT
| Q4 25 | $1.4B | $1.3B | ||
| Q3 25 | $1.4B | $1.3B | ||
| Q2 25 | $1.3B | $1.2B | ||
| Q1 25 | $1.3B | $1.2B | ||
| Q4 24 | $1.3B | $1.2B | ||
| Q3 24 | $1.3B | $1.2B | ||
| Q2 24 | $1.2B | $1.1B | ||
| Q1 24 | $1.2B | $1.1B |
总资产OFGVCYT
| Q4 25 | $12.5B | $1.4B | ||
| Q3 25 | $12.2B | $1.4B | ||
| Q2 25 | $12.2B | $1.3B | ||
| Q1 25 | $11.7B | $1.3B | ||
| Q4 24 | $11.5B | $1.3B | ||
| Q3 24 | $11.5B | $1.3B | ||
| Q2 24 | $11.3B | $1.2B | ||
| Q1 24 | $11.2B | $1.2B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $217.7M | $52.6M |
| 自由现金流经营现金流 - 资本支出 | $199.3M | $48.8M |
| 自由现金流率自由现金流/营收 | 108.1% | 34.7% |
| 资本支出强度资本支出/营收 | 10.0% | 2.7% |
| 现金转化率经营现金流/净利润 | 3.90× | 1.28× |
| 过去12个月自由现金流最近4个季度 | $345.4M | $126.6M |
8季度趋势，按日历期对齐
经营现金流OFGVCYT
| Q4 25 | $217.7M | $52.6M | ||
| Q3 25 | $39.5M | $44.8M | ||
| Q2 25 | $35.9M | $33.6M | ||
| Q1 25 | $83.1M | $5.4M | ||
| Q4 24 | $252.5M | $24.5M | ||
| Q3 24 | $58.1M | $30.0M | ||
| Q2 24 | $95.1M | $29.6M | ||
| Q1 24 | $61.0M | $-9.0M |
自由现金流OFGVCYT
| Q4 25 | $199.3M | $48.8M | ||
| Q3 25 | $35.5M | $42.0M | ||
| Q2 25 | $31.8M | $32.3M | ||
| Q1 25 | $78.7M | $3.5M | ||
| Q4 24 | $231.2M | $20.4M | ||
| Q3 24 | $51.8M | $27.7M | ||
| Q2 24 | $90.4M | $26.8M | ||
| Q1 24 | $54.8M | $-11.1M |
自由现金流率OFGVCYT
| Q4 25 | 108.1% | 34.7% | ||
| Q3 25 | 19.1% | 31.8% | ||
| Q2 25 | 17.4% | 24.8% | ||
| Q1 25 | 44.1% | 3.1% | ||
| Q4 24 | 126.5% | 17.2% | ||
| Q3 24 | 29.6% | 23.9% | ||
| Q2 24 | 50.3% | 23.4% | ||
| Q1 24 | 31.4% | -11.5% |
资本支出强度OFGVCYT
| Q4 25 | 10.0% | 2.7% | ||
| Q3 25 | 2.1% | 2.1% | ||
| Q2 25 | 2.3% | 1.0% | ||
| Q1 25 | 2.4% | 1.6% | ||
| Q4 24 | 11.7% | 3.5% | ||
| Q3 24 | 3.6% | 1.9% | ||
| Q2 24 | 2.6% | 2.4% | ||
| Q1 24 | 3.5% | 2.2% |
现金转化率OFGVCYT
| Q4 25 | 3.90× | 1.28× | ||
| Q3 25 | 0.76× | 2.34× | ||
| Q2 25 | 0.69× | — | ||
| Q1 25 | 1.82× | 0.76× | ||
| Q4 24 | 5.02× | 4.80× | ||
| Q3 24 | 1.24× | 1.98× | ||
| Q2 24 | 1.86× | 5.16× | ||
| Q1 24 | 1.23× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OFG
暂无分部数据
VCYT
| Testing | $135.8M | 97% |
| Products | $3.8M | 3% |
| Biopharmaceutical And Other | $686.0K | 0% |
